Spotlight on Pegfilgrastim in Chemotherapy-Induced Neutropenia

被引：0
作者：
James E. Frampton
Gillian M. Keating
机构：
[1] Adis International Inc.,
来源：
BioDrugs | 2005年 / 19卷
关键词：
Breast Cancer; Acute Myeloid Leukemia; Febrile Neutropenia; Filgrastim; Chemotherapy Cycle;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Pegfilgrastim (Neulasta®), the sustained-duration form of filgrastim (recombinant human granulocyte colony-stimulating factor [G-CSF]), is created by the addition of a polyethylene glycol (PEG) moiety to filgrastim. Its approved indication in the US is to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy.
引用
收藏
页码：405 / 407
页数：2
相关论文
共 77 条
[1]  
Molineux G.(2004)The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta®) Curr Pharm Des 10 1235-44
[2]  
Lord B.I.(2001)Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF) Clin Cancer Res 7 2085-90
[3]  
Woolford L.B.(2003)Pegylation: engineering improved biopharmaceuticals for oncology Pharmacotherapy 23 3S-8S
[4]  
Molineux G.(2000)Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy J Clin Oncol 18 2522-8
[5]  
Molineux G.(2002)Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer Ann Oncol 13 903-9
[6]  
Johnston E.(2003)A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy Ann Oncol 14 29-35
[7]  
Crawford J.(2003)Pharmacokinetics of pegfilgrastim Pharmacotherapy 23 9S-14S
[8]  
Blackwell S.(2005)First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study J Clin Oncol 23 1178-84
[9]  
Holmes F.A.(2002)Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer J Clin Oncol 20 727-31
[10]  
Jones S.E.(2003)Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma J Clin Oncol 21 514-9
12345678